Mr. Thomas Smeenk reports

HEMOSTEMIX APPOINTS DR. DAVID B. ALPER, TO LEAD MULTIDISCIPLINARY PHYSICIAN EDUCATION IN THE USE OF ACP-01

Hemostemix Inc. has appointed Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as multidisciplinary physician education lead and to its scientific advisory board, effective January, 2026.

Dr. Alper will work with Hemostemix on a focused set of physician-led education and clinical engagement initiatives, engaging with wound-care podiatrists and multidisciplinary limb-preservation teams, starting in Florida.

Dr. Alper will assist Hemostemix in executing three parallel initiatives.

Clinical practice engagement in Florida

Dr. Alper will engage with wound care podiatry practitioners and multidisciplinary limb salvage teams in Florida, to detail how VesCell (ACP-01) addresses pain and the ischemia root cause of peripheral arterial disease, diabetic foot ulcers and amputation. This effort is designed to support increased use of ACP-01 in each medical practice, following responsible clinical education and data-informed practice development.

Schools of podiatric medicine

Dr. Alper will engage deans of clinical education at U.S. schools of podiatry medicine. This initiative will introduce graduating doctors of podiatry and faculty on ACP-01 intervention.

Multidisciplinary education and professional forums

Dr. Alper will support Hemostemix's participation in multidisciplinary educational forums involving podiatrists, vascular specialists, interventional physicians, nurses and wound care professionals. Content will focus on ischemic disease phenotyping, patient selection, procedural considerations and ACP-01's integration into real-world team-based practices.

About Dr. David B. Alper

Dr. Alper is a nationally recognized podiatry physician and leader in wound care, limb preservation and diabetic foot management. He currently serves as a trustee of the American Podiatric Medical Association, is a fellow of the Royal College of Physicians and Surgeons of Glasgow, and has held numerous leadership and advisory roles across national wound care, diabetes and amputation prevention organizations. He is an inductee of the Hall of Fame, Kent State University College of Podiatry Medicine; serves as an adjunct professor in clinical education; serves as emeritus surgical staff at Mount Auburn Hospital; is a member of the leadership board of the American Diabetes Association, New England, where he served as president for over 20 years; is an elected member of the board of trustees of the American Podiatry Medical Association; served as chair of the Belmont (Massachusetts) board of health for 30 years; and currently sits on the Massachusetts Association of Health Boards.

A noted speaker, published writer and podcaster on a variety of podiatry topics including articles published in Prevention, Health Journal and Walking magazines, Dr. Alper has focused on limb amputation prevention, forming collaborations between medical societies in the diabetes, podiatry and vascular industries. He currently serves on the boards of the Wound Care Collaborative Community (WCCC), the Alliance for Woundcare Stakeholders and the foot ankle health section of the American Public Health Assocation; is co-chair of the professional and public education committee for the PAD Collaborative; is a board member of the medical advisory panel of the Amputation Prevention Alliance; and is a member of the Professional Communications Committee of the CLI Global Association.

Chief executive officer statement

"To welcome Dr. David Alper at the zenith of his extraordinary career to lead ACP-01 physician education in the USA is an incredible honour," said Thomas Smeenk, chief executive officer. "Dr. Alper is the nexus-personified of wound care/limb saving/life-saving treatments. There is no higher calling card. His message to his colleagues is that the scientific evidence of ACP-01 justifies the clinical know-how, to change the trajectory of these diseases. Saving a limb is saving a life. Dr. Alper is a major influencer to get that message across," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peerreviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, University of Britishi Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.